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It is well appreciated that majority of idiopathic 
pulmonary fibrosis (IPF) patients have gastric disorders 
including gastroesophageal reflux disease (GERD), 
dyspepsia and gastritis [1]. Accordingly, IPF patients are often 
prescribed antacid therapy such as histamine H2-receptor 
antagonists (H2RA) and proton pump inhibitors (PPIs). 
Occasionally, patients who repeatedly failed these medical 
interventions are referred to undergo surgical procedures to 
repair a segment of the esophagus and reinforce the closing 
function of the lower esophageal sphincter (LES). The later 
intervention is often more durable and effective in preventing 
the reflux of gastric juice and possible aspiration into the 
respiratory system [2]. However, despite limitations of the 
medical interventions, the use of H2RA and PPIs in IPF is 
still very common. Accordingly, a number of clinical studies 
have anecdotally and retrospectively assessed the safety and 
efficacy of antacid therapy in IPF. 
In the past, several studies have reported beneficial effect 
of antacids in IPF disease outcomes including lower loss in 
pulmonary function, prolonged median survival and fewer 
episodes of acute exacerbations [3-6]. By contrast, a recent 
study by Kreuter et al. [7] published in Lancet Respiratory 
Medicine analyzed data pooled from three large clinical trials 
(CAPACITY 004, 006 and ASCEND) that primarily 
evaluated the safety and efficacy of pirfenidone and reported 
no benefit and a possible harm associated with the use of 
antacid therapy in IPF. This report was illuminated by a 
commentary from Nathan [8].   
The two reports appear to be highly polarized and 
dismissive of the recent evidence-based guidelines for the 
treatment of IPF that conditionally recommended the use of 
antacid therapy in IPF [9]. However, it is important to 
highlight some important insights before overdrawing 
conclusions and making any changes to the 
recommendations by the Thoracic Societies: 1) why was only 
the data from patients in the placebo arm of the pirfenidone 
study presented in the publication? 2) would it not make 
more sense to have also analyzed and concurrently reported 
data from patients who were taking pirfenidone in the 
absence or presence of antacids? 3) were there findings in the 
study that appear to be downplayed or exaggerated? 4) what 
does the data (pertaining to question 2 above) that was not 
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reported look like? 5) how did the declared conflict of 
interest of the authors, including personal fees and grants 
influence partiality? 6) why was it absolutely necessary for 
one of the makers of a drug marketed for IPF to closely 
supervise the analysis and reporting of the study including 
paying for a ghost writer? 7) did the study provide enough 
evidence to compel a change in the guidelines? 8) what are 
some of the key differences between this study and some of 
the previous studies that favored the use of antacid therapy? 
9) does the use of antacid therapy or surgery provide any
possible benefit (or harm) to IPF patients? 10) what is the
way forward regarding the use of antacids in IPF?
As discussed by Kreuter et al [7], the study, like other 
retrospective studies, has inherent limitations including the 
influence of confounders such as comorbidities and 
co-prescriptions. However, the study by Kreuter has 
additionally been compromised by entering and exiting of 
uneven number of patients to and out of the antacid therapy 
group. This crossing over, unless handled properly, may 
enable the latecomers to antacid therapy to simply be 
classified as ‘no antacid therapy group’ and compete against 
these who were on antacid therapy at baseline. To complicate 
matters, there is no information regarding the continued use 
of antacid therapy by these who were taking the therapy at 
baseline. One is simply led to take these important variables 
at face value and hone into the interpretation of results and 
conclusion. 
At best, it is difficult to draw any firm conclusion from the 
unadjusted dataset (presented in Table 3 and Table 4) they 
provided since the patients in the antacid group had 
significantly higher GER-related and cardiovascular 
morbidity at baseline. Unfortunately, Kreuter et al not only 
have relied on unadjusted data (Table 4) to report how 
significantly the use of antacid therapy increased the risk of 
infection but also made this statement to be the main finding 
of the study. This flawed and exaggerated conclusion 
requires caution by every clinician who treats IPF patients 
and especially those who are recent graduates and 
doctors-in-training. If at all, it was only a subset of the 
sickest IPF patients in the antacid group that experienced 
increased risk of infection. However, this cannot and should 
not be pinned to the use of antacid therapy as the set of data 
that led to this conclusion is not adjusted and as a result is 
likely to have been influenced by several unaccounted 
variables. Meanwhile, the biased conclusion and unfair 
interpretation of the unadjusted data has confounded some 
important findings in the adjusted part of their analysis 
(Table 5). This Table shows that the use of antacid therapy 
numerically favored, without reaching statistical 
significance: i) progression-free survival, ii) all-cause 
mortality, iii) death or 6 minute walk distance (6MWD) 
decrease by 10% or more, and iv) IPF-related mortality 
(p=0.077) (Figure 1A above). Unfortunately, the authors 
have largely ignored discussing any of these potentially 
favorable outcomes associated with the use of antacid 
therapy. In addition, citing “data not shown”, they revealed 
that poor compliance with antacid therapy might be 
associated with increased mortality. However, this possibility 
was swiftly rejected by the authors.  
Meanwhile, their finding that was not reported (for one 
reason or another) in this study but was presented at the 
Figure 1. Odds ratio of adjusted data showing the effect of antacid therapy at 1-year when: A) compared with placebo or B) 
combined with pirfenidone. Odds ratio (median value) and 95% CI is shown in both dataset. Dataset A is drawn from Table 5 of Kreuter et 
al7 and Dataset B is re-drawn from data presented by Kreuter et al ATS 201610. 
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recent American Thoracic Society (ATS) meeting in San 
Francisco (Abstract A2689 and Poster 201) [10] is even more 
stimulating. This study analyzed data from patients who were 
in the pirfenidone arm (of the above three large clinical 
trials) in the presence or absence of antacid therapy. This 
study had 273 patients in the pirfenidone plus antacid group 
and 350 patients in the pirfenidone without antacid group. 
Their unadjusted data showed that the use of antacid therapy 
significantly reduced the decline in lung function by 10% or 
more (p=0.0273). Similarly, their adjusted data numerically 
favored the use of antacid therapy for: i) progression-free 
survival, ii) all-cause mortality, iii) death or 6MWD decrease 
by 10% or more and iv) IPF-related mortality (Figure 1B 
above). Intriguingly, this set of data has its own merits as it 
eludes to the possible benefit of combining the use of 
pirfenidone with antacid therapy. In particular, since it is 
most likely that any emerging drug for IPF has to be tested in 
combination with the standard of care (e.g. pirfenidone).    
In addition, the significance in overall infections they 
reported in the Lancet Respiratory Medicine paper did not 
stay significant in the second (i.e. pirfenidone plus antacid) 
analysis. Now, since the authors and Nathan made so much 
ado about unadjusted data, would it not be appropriate to 
make similar claims about the significant or numerically 
trended benefits associated with the use of antacid therapy in 
IPF from these two studies? As Nathan wrote, there may not 
be a “commercial appetite” with testing and developing 
antacid therapy for IPF. However, if proven to be effective in 
prospective studies, a combination of pirfenidone with 
antacid therapy may actually reduce the hefty dose (over 2 
grams a day) and cost (over 90,000/patient/year) of 
pirfenidone and make a treatment plan more affordable and 
accessible for IPF patients who deserve the best possible 
treatment at the lowest possible cost. Meanwhile, any 
possible increase in risk of respiratory infection associated 
with antacids or GERD may be managed on a case-by-case 
basis while allowing patients to possibly benefit from antacid 
therapy in their IPF-related disease outcomes. This is 
particularly appealing especially given the several other 
retrospective clinical studies that reported significant benefit 
associated with the use of antacid therapy in IPF.[4-6]  
However, such prospect may well be against the money 
making scheme of industry and for that reason alone, a 
prospective study evaluating the use of antacid therapy (e.g. 
PPIs) as stand-alone or add-on to the already approved drugs 
may never be pursued.  
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